Q/C Technologies, Inc. has entered into an Omnibus Amendment Agreement with PharmaCyte Biotech, Inc. dated November 20, 2026. PharmaCyte holds a majority of the outstanding shares of the Company’s Series G and Series H convertible preferred stock, qualifying it as the Required Holders under the terms of those securities.
The agreement involves amendments to the Certificate of Designations for both preferred stock series. The Company filed Certificates of Amendment with the Secretary of State of Delaware on November 20, 2026. These filings amended the amendment provisions and the beneficial ownership limitations contained within the Series G and Series H Certificates of Designations.
In addition to the Omnibus Agreement, the Company filed a separate Certificate of Amendment on November 20, 2026. This document, filed as Exhibit 3.3 to the current report, amends the Series H Certificate of Designations to extend the maturity date of the Series H Preferred Stock from March 2, 2027, to September 2, 2027.
The Company previously disclosed that on May 20, 2024, it issued Series G Preferred Stock and warrants to accredited investors. On September 2, 2025, the Company issued Series H Preferred Stock and accompanying warrants to the same group of investors. All amendments referenced in this report are incorporated by reference to the full text of the agreements and exhibits filed with the SEC.